AVTX Avalo Therapeutics, Inc.

NASDAQ
$6.75

Avalo Therapeutics, Inc. (AVTX) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.49 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.2% since its last earnings release on November 5, 2026.

Avalo Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.49)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Avalo Therapeutics, Inc.

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.